84,000 Shares in Alignment Healthcare, Inc. $ALHC Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. acquired a new position in Alignment Healthcare, Inc. (NASDAQ:ALHC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 84,000 shares of the company’s stock, valued at approximately $1,176,000.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Alignment Healthcare by 13.2% during the first quarter. Vanguard Group Inc. now owns 11,113,896 shares of the company’s stock valued at $206,941,000 after buying an additional 1,295,825 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Alignment Healthcare by 5.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 9,078,113 shares of the company’s stock valued at $169,035,000 after acquiring an additional 429,071 shares during the period. Wellington Management Group LLP boosted its holdings in Alignment Healthcare by 0.9% during the 1st quarter. Wellington Management Group LLP now owns 7,509,057 shares of the company’s stock valued at $139,819,000 after acquiring an additional 70,557 shares during the period. 8 Knots Management LLC grew its position in Alignment Healthcare by 28.9% in the 1st quarter. 8 Knots Management LLC now owns 4,715,472 shares of the company’s stock valued at $87,802,000 after acquiring an additional 1,056,777 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Alignment Healthcare by 9.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,199,421 shares of the company’s stock worth $40,954,000 after purchasing an additional 193,644 shares during the period. Institutional investors own 86.19% of the company’s stock.

Insiders Place Their Bets

In other Alignment Healthcare news, Director Atlantic (Aln Hlth) L. General sold 6,246,096 shares of the firm’s stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $16.01, for a total value of $99,999,996.96. Following the completion of the sale, the director directly owned 24,596,079 shares in the company, valued at $393,783,224.79. This trade represents a 20.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Joseph S. Konowiecki sold 25,000 shares of Alignment Healthcare stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $18.00, for a total transaction of $450,000.00. Following the completion of the transaction, the director directly owned 1,085,973 shares in the company, valued at $19,547,514. This represents a 2.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 7,427,716 shares of company stock worth $119,650,069. Insiders own 6.60% of the company’s stock.

Alignment Healthcare Trading Up 1.5%

NASDAQ ALHC opened at $17.09 on Wednesday. Alignment Healthcare, Inc. has a one year low of $10.18 and a one year high of $21.06. The company has a debt-to-equity ratio of 1.99, a quick ratio of 1.61 and a current ratio of 1.61. The company has a market capitalization of $3.42 billion, a price-to-earnings ratio of -142.42 and a beta of 1.17. The company’s 50-day simple moving average is $16.94 and its two-hundred day simple moving average is $15.46.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03. The firm had revenue of $993.70 million during the quarter, compared to analysts’ expectations of $980.90 million. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. The company’s revenue was up 43.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.14) EPS. Alignment Healthcare has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ALHC. Zacks Research lowered shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Barclays lifted their price objective on shares of Alignment Healthcare from $13.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday. KeyCorp upgraded shares of Alignment Healthcare from a “sector weight” rating to an “overweight” rating and set a $21.00 target price on the stock in a research note on Monday, August 25th. Wall Street Zen lowered shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a research report on Sunday, August 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alignment Healthcare in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.75.

Alignment Healthcare Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.